
Jefferies cuts PT on defense contractor Leidos LDOS.N to $215 from $230, rating maintained at "buy"
New PT implies an upside of 24% from the stock's last close
Brokerage flags soft 2026 outlook as the key overhang, pointing to continued weakness in health segment and the slip of several major awards into early next year
Adds that co's sharply higher 2026 capex will temporarily push free cash flow down and limit buyback activity
Eight of 16 brokerages rate the stock "buy" or higher, eight "hold"; their median PT is $215- data compiled by LSEG
As of last close, shares down 3.8% YTD